Amyloidosis AA;Amylose AA

Nephrologie et Therapeutique

Volumn 4, Issue 4, 2008, Pages 281-287

  Stankovic, Katia ^a,b,c   Grateau, Gilles ^a,b,c  

^a HÔPITAL TENON   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c Centre de reference des amyloses d'origine inflammatoire et de la fievre mediterraneenne familiale   (France)

Author keywords

Amylose; Immunohistochemistry; Nephropathy; Protein SAA

Indexed keywords

AMYLOID A PROTEIN; CHLORAMBUCIL; COLCHICINE; CREATININE; CYCLOPHOSPHAMIDE; SERUM AMYLOID A;

ACUTE PHASE RESPONSE; AMYLOIDOSIS; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; AUTOINFLAMMATORY DISEASE; CHRONIC INFLAMMATION; CREATININE BLOOD LEVEL; HEREDITY; HUMAN; IMMUNOHISTOCHEMISTRY; INCIDENCE; KIDNEY FAILURE; PATHOPHYSIOLOGY; PROGNOSIS; PROTEINURIA; RHEUMATOID ARTHRITIS; SHORT SURVEY; SPONDYLOARTHROPATHY;

AMYLOIDOSIS; AUTOPSY; HUMANS; INFLAMMATION; SERUM AMYLOID A PROTEIN;

EID: 45849148881     PISSN: 17697255     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nephro.2008.02.002     Document Type: Short Survey

References (29)

1. Simms R.W., Prout M.N., and Cohen A.S. The epidemiology of AL and AA amyloidosis. In: Husby G. (Ed). Reactive amyloidosis and the acute phase response, Baillière's Clinical Rheumatology (1994), Baillière's Tindall, London 627-634
2. Hazenberg B.P., and van Rijswijk M.H. Amylose AA. In: Grateau G., Benson M.D., and Delpech M. (Eds). Les amyloses (2000), Flammarion Médecine-Sciences, Paris 377-427
3. Lachmann H.J., Gilbertson J.A., Gillmore J.D., Hawkins P.N., and Pepys M.B. Unicentric Castleman's disease complicated by systemic AA amyloidosis: a curable disease. Q J Med 95 (2002) 211-218
4. Husby G. Amyloidosis and rheumatoid arthritis. Clin Exp Rheum 3 (1985) 173-180
5. Escalante A., Weaver W.J., and Beardmore T.D. An estimate of the prevalence of reactive systemic amyloidosis in ankylosing spondylitis. J Rheumatol 22 (1995) 2192-2193
6. Gratacos J., Orellana C., Sanmarti R., Sole M., Collado A., Gomez-Casanovas E., et al. Secondary amyloidosis in ankylosing spondylitis. A systematic survey of 137 patients using abdominal fat aspiration. J Rheumatol 24 (1997) 912-915
7. Gomez-Casanovas E., Sanmarti R., Sole M., Canete J.D., and Munoz-Gomez J. The clinical significance of amyloid fat deposits in rheumatoid arthritis: a systematic long-term followup study using abdominal fat aspiration. Arthritis Rheum 44 (2001) 66-72
8. Uda H., Yokota A., Kobayashi K., Miyake T., Fushimi H., Maeda A., et al. Two distinct clinical courses of renal involvement in rheumatoid patients with AA amyloidosis. J Rheumatol 33 (2006) 1482-1487
9. Verine J., Mourad N., Desseaux K., Vanhille P., Noėl L.-H., Beaufils H., et al. Clinical and histological characteristics of renal AA amyloidosis: a retrospective study of 68 cases with a special interest to amyloid-associated inflammatory response. Hum Pathol 38 (2007) 1798-1809
10. Ylinen K., Grönhagen-Riska C., Honkanen E., Ekstrand A., Metsarinne K., and Kuhlback B. Outcome of patients with secondary amyloidosis in dialysis treatment. Nephrol Dial Transplant 7 (1992) 908-912
11. Gal R., Shtrasburg S., Luria M., Lifschitz Mercer B., Viskin S., Yakar S., et al. Amyloid goiter: report of the clinical, histological and biochemical features of five cases. Amyloid 2 (1995) 119-125
12. Danby P., Harris K.P.G., Williams B., Feehally J., and Walls J. Adrenal dysfunction in patients with renal amyloid. Q J Med 76 (1990) 915-922
13. Hachulla E., Janin A., Flipo R.M., Saile R., Facon T., Bataille D., et al. Labial salivary gland biopsy is a reliable test for the diagnosis of primary and secondary amyloidosis: a prospective clinical and immunohistologic study in 59 patients. Arthritis Rheum 36 (1993) 691-697
14. Grateau G, Jéru I, Rouaghe S, Cazeneuve C, Ravet N, Duquesnoy P, et al. Amyloidosis and auto-inflammatory syndromes. In: Kostanpopoulos K, editor. Inflammation and auto-inflammation. Pathophysiology and molecular aspects. Curr Drug Target Inflamm Allergy 2005;4(Special Issue):57-65.
15. Lachmann H.J., Goodman H.J.B., Gilbertson J.A., Gallimore J.R., Sabin C.A., Gillmore J.D., et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 356 (2007) 2361-2371
16. Booth D.R., Booth S.E., Gillmore J.D., Hawkins P.N., and Pepys M.B. SAA1 alleles as risk factors in reactive systemic AA amyloidosis. Amyloid 5 (1998) 262-265
17. Cazeneuve C., Ajrapetyan H., Papin S., Roudot-Thoraval F., Genevieve D., Mndjoyan E., et al. Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. Am J Hum Genet 67 (2000) 1136-1143
18. Gershoni-Baruch R., Brik R., Zacks N., Shinawi M., Lidar M., and Livneh A. The contribution of genotypes at the MEFV and SAA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever. Arthritis Rheum 48 (2003) 1149-1155
19. Yamada T., Okuda Y., Takasugi K., Wang L., Marks D., Benson M.D., et al. An allele of serum amyloid A1 associated with amyloidosis in both Japanese and Caucasians. Amyloid 10 (2003) 7-11
20. ® in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med 314 (1986) 1001-1005
21. ® dosage in familial Mediterranean fever. Clin Exp Rheumatol 21 (2003) 509-514
22. Savolainen H.A., and IsomÄki H.A. Decrease in the number of deaths from secondary amyloidosis in patients with juvenile rheumatoid arthritis. J Rheumatol 20 (1993) 1201-1203
23. Ortiz-Santamaria V., Olive A., Valls-Roc M., and Tena X. Treatment of AA amyloid with chlorambucil. Rheumatology (Oxford) 41 (2002) 833
24. Chevrel G., Jenvrin C., McGregor B., and Miossec P. Renal type AA amyloidosis associated with rheumatoid arthritis: a cohort study showing improved survival on treatment with pulse cyclophosphamide. Rheumatology (Oxford) 40 (2001) 821-825
25. Gottenberg J.E., Merle-Vincent F., Bentaberry F., Allanore Y., Berenbaum F., Fautrel B., et al. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy. Arthritis Rheum 48 (2003) 2019-2024
26. Fernandez-Nebro A., Tomero E., Ortiz-Santamaria V., Castro M.C., Olive A., De Haro M., et al. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists. Am J Med 118 (2005) 552-556
27. Kisilevsky R., Lemieux L.J., Fraser P.E., Kong X., Hultin P.G., and Szarek W.A. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nature Med 1 (1995) 143-148
28. Pepys M.B., Herbert J., Hutchinson W.L., Tennent G.A., Lachmann H.J., Gallimore J.R., et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 417 (2002) 254-259
29. Bollée G., Guery B., Joly D., Snanoudj R., Terrier B., Allouache M., et al. Presentation and Outcome of Patients with Systemic Amyloidosis Undergoing Dialysis. Clin J Am Soc Nephrol (2008 Jan 9) Epub ahead of print